GlycoNex Inc. is a Taiwan-based company principally engaged in the development and licensing of anti-cancer monoclonal antibodies, as well as the provision of carbohydrate antigen and protein drug related commission services. The Company is mainly involved in the development of anti-cancer monoclonal antibody new drugs and bio-similar drugs, as well as the licensing of monoclonal antibody targets and carbohydrate antigen and protein drug related services. The Company distributes its products in domestic market and to overseas markets, such as the rest areas of Asia.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
26-07-08	NT$25.65	-0.58%	189,707
26-07-07	NT$25.80	-2.09%	423,083
26-07-06	NT$26.35	+3.33%	653,130
26-07-03	NT$25.50	+0.79%	260,868
26-07-02	NT$25.30	+0.60%	188,011

End-of-day quote Taipei Exchange

More quotes

Income Statement and Estimates

More financial data

End-of-day quote Taipei Exchange Other stock markets 2026-07-08			5-day change	1st Jan Change
25.65 ^TWD	-0.58%		+0.20%	-0.39%

06-10	Glyconex Announces Positive Topline Results for Phase III Clinical Trial of Denosumab Biosimilar Spd8	CI
05-14	GlycoNex Incorporation Reports Earnings Results for the First Quarter Ended March 31, 2026	CI

Market Cap	2.89B 89.89M 78.63M 72.57M 67.02M 127M 8.59B 130M 870M 339M 4.22B 338M 330M 14.62B	P/E 2024	-11.8x	P/E 2025	-11.9x
Enterprise Value	2.67B 83.05M 72.65M 67.05M 61.92M 118M 7.93B 120M 804M 313M 3.9B 312M 305M 13.5B	EV / Sales 2024	154x	EV / Sales 2025	67.8x
Free-Float	80.91%	Yield 2024 *	-	Yield 2025	-

06-10	Glyconex Announces Positive Topline Results for Phase III Clinical Trial of Denosumab Biosimilar Spd8	CI
05-14	GlycoNex Incorporation Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-14	GlycoNex, Inc Receives PMDA Approval To Initiate First-In-Human Phase 1 Trial Of GNX1021 In Gastrointestinal Cancers	CI
03-23	GlycoNex Inc. And Nippon Kayaku Co., Ltd. Enters Collaboration To Advance Next-Generation ADC Candidate	CI
03-13	GlycoNex Incorporation Reports Earnings Results for the Full Year Ended December 31, 2025	CI
12-08	GlycoNex Signs CDMO Service Agreement with Change Cure to Advance HMGB1-Targeted Antibody Program	CI
11-24	Glyconex, Inc. and Hokkaido University Hospital Launch Study to Advance Glycan-Directed ADC Development in Gastric Cancer	CI
11-14	GlycoNex Incorporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
25-10-29	GlycoNex announces last patient dosed in phase 3 trial of SPD8, a denosumab biosimilar for osteoporosis	RE
25-10-29	GlycoNex, Inc. Announces Last Patient Dosed in Phase 3 Trial of SPD8, a Denosumab Biosimilar for Osteoporosis	CI
25-08-13	GlycoNex Incorporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
25-06-12	GlycoNex, Inc. Announces Publication of Preclinical Study on Gnx1021, A Novel Glycan-Targeted Adc for Gastric Cancer	CI
25-05-27	GlycoNex, Inc. Announces Publication of Research Involving Pro-Antibody, GNX201, in the International Journal of Biological Macromolecules	CI

1 day	-0.58%
1 week	+0.20%
Current month	+0.20%
1 month	-1.72%
3 months	+11.04%
Current year	-0.39%

GlycoNex Incorporation Stock

Stocks

4168

TW0004168000

Biotechnology & Medical Research

Valuation: GlycoNex Incorporation

Chart: GlycoNex Incorporation

Latest news : GlycoNex Incorporation

Press Releases: GlycoNex Incorporation

Quotes and Performance

Course Extremes

Managers and Directors: GlycoNex Incorporation

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Income Statement and Estimates

1 week	25.2	26.7
1 month	24.6	30
Current year	22.1	30
1 year	20.55	30
3 years	15.6	32.9
5 years	15.6	46.9
10 years	10.2	46.9

Manager	Title	Age	Since
Mei Chun Yang CEO	Chief Executive Officer	-	2018-12-31
Dih Fen Wu DFI	Director of Finance/CFO	-	2009-12-31
Yao Hua Lue IRC	Investor Relations Contact	-	2012-11-11

Director	Title	Age	Since
Tong Hsuan Chang CHM	Chairman	-	2001-01-31
Kao Chung Tsai BRD	Director/Board Member	64	-
Ling-Chun Tsai BRD	Director/Board Member	-	2012-05-24

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
GLYCONEX INCORPORATION	-0.58%	+0.20%	+9.15%	-18.05%	90.33M
LONZA GROUP AG	-0.24%	+4.98%	+2.69%	+9.14%	49.74B
REVOLUTION MEDICINES, INC.	-0.36%	+1.33%	+417.51%	+619.10%	40.49B
BEONE MEDICINES AG	-2.29%	+5.93%	+25.27%	+59.26%	34.35B
IQVIA HOLDINGS INC.	-2.13%	+5.47%	+25.45%	-6.01%	34.75B
CELLTRION, INC.	-0.79%	+2.02%	+3.83%	+36.42%	26.98B
ASCENDIS PHARMA A/S	+3.82%	+3.92%	-	-	16.58B
MEDPACE HOLDINGS, INC.	-2.62%	+0.45%	+66.82%	+125.87%	15.6B
IONIS PHARMACEUTICALS, INC.	-2.17%	+6.52%	+102.15%	+102.15%	14.27B
EUROFINS SCIENTIFIC SE	-2.70%	-2.19%	+11.25%	+18.19%	13.76B
Average	-1.01%	+3.73%	+73.79%	+105.12%	24.66B
Weighted average by Cap.	-1.00%	+4.36%	+93.68%	+139.12%

	2024	2025
Net sales	14.7M 458K 401K 370K 341K 648K 43.75M 661K 4.43M 1.72M 21.48M 1.72M 1.68M 74.44M	37.86M 1.18M 1.03M 952K 879K 1.67M 113M 1.7M 11.41M 4.44M 55.31M 4.43M 4.33M 192M
Net income	-230M -7.15M -6.26M -5.78M -5.33M -10.13M -684M -10.33M -69.25M -26.95M -336M -26.86M -26.28M -1.16B	-235M -7.33M -6.41M -5.91M -5.46M -10.37M -700M -10.57M -70.91M -27.6M -344M -27.51M -26.91M -1.19B
Net Debt	-442M -13.77M -12.05M -11.12M -10.27M -19.49M -1.32B -19.87M -133M -51.86M -646M -51.7M -50.57M -2.24B	-220M -6.84M -5.99M -5.52M -5.1M -9.69M -654M -9.88M -66.23M -25.77M -321M -25.69M -25.13M -1.11B